Amgen stock slips 3% following Phase 3 data for rocatinlimab, Uplizna
Amgen shares slipped 3% in post-market trading after it reported Phase 3 data for two of its drugs, Uplizna and rocatinlimab, ...
Zacks.com on MSN1mon
AMGN Stock Falls Despite Upbeat Data on Immunology Drugs: Here's Why
The HORIZON study evaluated an investigational anti-OX40 therapy rocatinlimab in atopic dermatitis (AD or eczema) indication.
BioWorld1mon
Amgen’s rocatinlimab data underwhelm in atopic dermatitis trial
While data from the Rocket Horizon study showed rocatinlimab hit all co-primary and secondary endpoints, the early findings fell below expectations in a highly competitive market.
Yahoo Finance1mon
Amgen's Rocatinlimab Data Beats Placebo In Atopic Dermatitis Trial, But Analyst Says Data Raises Concerns Amid Competitive Market
In an investor update on Tuesday, Amgen Inc (NASDAQ:AMGN) released data from Phase 3 trials of rocatinlimab and Uplizna (inebilizumab). HORIZON Phase 3 trial evaluated rocatinlimab for atopic ...
Benzinga.com23d
Sanofi (NASDAQ:SNY) Stock Quotes, Forecast and News Summary
Amgen releases Phase 3 trial data for rocatinlimab and Uplizna, with analysts projecting strong sales despite competition in the atopic dermatitis and myasthenia gravis markets. Attention shifts ...